BR9909736A - Formulação farmacêutica de aerossol, processo para preparação de uma formulação farmacêutica de aerossol, partìculas de princìpios ativos farmacêuticos, e, cartucho - Google Patents

Formulação farmacêutica de aerossol, processo para preparação de uma formulação farmacêutica de aerossol, partìculas de princìpios ativos farmacêuticos, e, cartucho

Info

Publication number
BR9909736A
BR9909736A BR9909736-2A BR9909736A BR9909736A BR 9909736 A BR9909736 A BR 9909736A BR 9909736 A BR9909736 A BR 9909736A BR 9909736 A BR9909736 A BR 9909736A
Authority
BR
Brazil
Prior art keywords
pharmaceutical
aerosol formulation
particles
cartridge
preparing
Prior art date
Application number
BR9909736-2A
Other languages
English (en)
Inventor
Pascal Cavaillon
Nathalie Llorca
Olivier Louis
Patrick Rosier
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808152.4A external-priority patent/GB9808152D0/en
Priority claimed from GBGB9814709.3A external-priority patent/GB9814709D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9909736A publication Critical patent/BR9909736A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMULAçãO FARMACêUTICA DE AEROSSOL, PROCESSO PARA PREPARAçãO DE UMA FORMULAçãO FARMACêUTICA DE AEROSSOL, PARTìCULAS DE PRINCìPIOS ATIVOS FARMACêUTICOS, E, CARTUCHO'' A presente invenção refere-se às novas formulações farmacêuticas de aerossol compreendendo: (A) um agente terapêutico na forma de partículas revestidas por pelo menos um excipiente de revestimento e pelo menos um tensoativo, em suspensão em (B) um gás propelente liq³efeito para a administração dos agentes terapêuticos particularmente por rota pulmonar, e a um processo para preparação destas formulações. Também se refere às novas partículas apropriadas para uso em tais formulações.
BR9909736-2A 1998-04-18 1999-04-15 Formulação farmacêutica de aerossol, processo para preparação de uma formulação farmacêutica de aerossol, partìculas de princìpios ativos farmacêuticos, e, cartucho BR9909736A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9808152.4A GB9808152D0 (en) 1998-04-18 1998-04-18 Pharmaceutical aerosol formulation
GBGB9814709.3A GB9814709D0 (en) 1998-07-08 1998-07-08 Pharmaceutical aerosol formulation
PCT/EP1999/002535 WO1999053901A1 (en) 1998-04-18 1999-04-15 Pharmaceutical aerosol formulation

Publications (1)

Publication Number Publication Date
BR9909736A true BR9909736A (pt) 2000-12-19

Family

ID=26313483

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909736-2A BR9909736A (pt) 1998-04-18 1999-04-15 Formulação farmacêutica de aerossol, processo para preparação de uma formulação farmacêutica de aerossol, partìculas de princìpios ativos farmacêuticos, e, cartucho

Country Status (30)

Country Link
US (1) US7521042B2 (pt)
EP (1) EP1073417B1 (pt)
JP (1) JP2002512183A (pt)
KR (1) KR20010042816A (pt)
CN (1) CN1145478C (pt)
AP (1) AP2000001961A0 (pt)
AR (1) AR018183A1 (pt)
AT (1) ATE228823T1 (pt)
AU (1) AU755066B2 (pt)
BR (1) BR9909736A (pt)
CA (1) CA2328882A1 (pt)
CO (1) CO5021210A1 (pt)
DE (1) DE69904312T2 (pt)
DK (1) DK1073417T3 (pt)
EA (1) EA200000956A1 (pt)
EE (1) EE200000608A (pt)
ES (1) ES2189410T3 (pt)
HR (1) HRP20000689A2 (pt)
HU (1) HUP0101608A2 (pt)
ID (1) ID27887A (pt)
IL (1) IL139087A0 (pt)
IS (1) IS5665A (pt)
MA (1) MA26621A1 (pt)
NO (1) NO20005218L (pt)
NZ (1) NZ507619A (pt)
PE (1) PE20000433A1 (pt)
PL (1) PL343491A1 (pt)
PT (1) PT1073417E (pt)
TR (1) TR200100144T2 (pt)
WO (1) WO1999053901A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
ES2193069T3 (es) 1999-04-14 2003-11-01 Glaxo Group Ltd Formulacion farmaceutica en aerosol.
PT2283817T (pt) † 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
KR20100107083A (ko) * 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN1791386A (zh) * 2003-05-19 2006-06-21 巴克斯特国际公司 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
US7448389B1 (en) 2003-10-10 2008-11-11 Materials Modification, Inc. Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
RU2007133547A (ru) * 2005-02-10 2009-03-20 Глаксо Груп Лимитед (GB) Способы получения лактозы с использованием методов предварительной сортировки и приготовляемые из нее фармацевтические композиции
WO2008000042A1 (en) 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
EP3620154A1 (en) 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
JP5809985B2 (ja) 2009-02-26 2015-11-11 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
SI2453894T1 (sl) 2009-07-15 2016-02-29 Theravance Biopharma R&D Ip, Llc Kristalinična oblika proste baze bifenilne spojine
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
CA2828833C (en) 2010-03-03 2020-11-03 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
WO2011155451A1 (ja) 2010-06-08 2011-12-15 学校法人神戸学院 コーティング粒子及びコーティング粒子の製造方法
WO2012083178A1 (en) 2010-12-17 2012-06-21 Neo Oncology Inc. Methods and devices for using isoperillyl alcohol
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
ES2600928T3 (es) 2010-08-27 2017-02-13 Neonc Technologies Inc. Composiciones farmacéuticas que comprenden derivados de alcohol perilílico
CN102366405A (zh) * 2011-10-21 2012-03-07 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的氟替卡松丙酸酯气雾剂制剂
WO2013128283A2 (en) 2012-02-28 2013-09-06 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
SI2968313T1 (en) 2013-03-15 2018-05-31 Verona Pharma Plc Combination of medicines
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
EP3872069A1 (en) 2015-02-12 2021-09-01 Neonc Technologies, Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
CN106546751A (zh) * 2016-11-16 2017-03-29 广州华弘生物科技有限公司 用于检测oct4蛋白的酶联免疫试剂盒
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
BR112020016074A2 (pt) 2018-02-08 2020-12-08 Neonc Technologies, Inc Métodos de permeabilização da barreira hematoencefálica

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
PT85521B (pt) * 1986-08-11 1990-06-29 Innovata Biomed Ltd Processo para a preparacao de composicoes farmaceuticas que consistem em microcapsulas
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
EP0834314B1 (en) * 1995-06-12 2003-01-15 Ono Pharmaceutical Co., Ltd. Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
AU5806998A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes

Also Published As

Publication number Publication date
WO1999053901A1 (en) 1999-10-28
ES2189410T3 (es) 2003-07-01
IL139087A0 (en) 2001-11-25
HUP0101608A2 (hu) 2002-03-28
ID27887A (id) 2001-05-03
EP1073417B1 (en) 2002-12-04
NO20005218D0 (no) 2000-10-17
US7521042B2 (en) 2009-04-21
EE200000608A (et) 2001-08-15
CO5021210A1 (es) 2001-03-27
KR20010042816A (ko) 2001-05-25
AU755066B2 (en) 2002-12-05
DK1073417T3 (da) 2003-03-24
ATE228823T1 (de) 2002-12-15
EP1073417A1 (en) 2001-02-07
CN1305369A (zh) 2001-07-25
NO20005218L (no) 2000-11-10
EA200000956A1 (ru) 2001-04-23
CN1145478C (zh) 2004-04-14
CA2328882A1 (en) 1999-10-28
AP2000001961A0 (en) 2000-12-31
TR200100144T2 (tr) 2001-06-21
PE20000433A1 (es) 2000-05-26
DE69904312T2 (de) 2003-10-16
JP2002512183A (ja) 2002-04-23
HRP20000689A2 (en) 2001-02-28
DE69904312D1 (de) 2003-01-16
MA26621A1 (fr) 2004-12-20
PT1073417E (pt) 2003-04-30
AU3523199A (en) 1999-11-08
US20030157032A1 (en) 2003-08-21
AR018183A1 (es) 2001-10-31
PL343491A1 (en) 2001-08-27
IS5665A (is) 2000-10-13
NZ507619A (en) 2003-05-30

Similar Documents

Publication Publication Date Title
AP2000001961A0 (en) Pharmaceutical aerosol formulation.
HRP20000867B1 (en) Pharmaceutical formulations for aerosols with two or more active substances
ATE233084T1 (de) Pharmazeutische aerosolformulierung
BR9916829A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol
BR9712125A (pt) Formulação farmaucêutica em aerosol, uso de uma mistura, produto farmacêutico, e, processo de administração de budesonida a um paciente
DE60126599D1 (de) Cannabis enthaltende pharmazeutische zusammensetzungen
ATE216575T1 (de) Treibgasmischung für eine aerosolzubereitung
NO972781L (no) Aerosolformuleringer av peptider og proteiner
HUP9802391A2 (hu) Inhaláló berendezés szalmeterol adagolására mért dózisban
YU59092A (sh) Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
YU56600A (sh) Uređaj za raznošenje aktivnog agensa u pluća pacijenta
PL336885A1 (en) Therapeutic products in the aerosol form
BR9916865A (pt) Composição farmacêutica em aerossol contendohfa 227 e hfa 134a
ATE157867T1 (de) Geschmacksmaskierende zusammensetzungen von ranitidin
ES2089011T3 (es) Excipiente lipidico de administracion nasal y aplicacion topica.
DK1223915T3 (da) Törpulverpræparater med forbedret dispersivitet
DK1435909T3 (da) Stabil sammensætning indeholdende partikler i en frossen vandig matrix
HRP20010463B1 (hr) Smjesa s kontroliranim otpuštanjem koja sadrži galantamin
HUP0000520A2 (hu) Új vizes gyógyszerkészítmények hajtógázmentes aeroszolokhoz
HRP20010243B1 (hr) Pripravci koji sadrže difosfonske kiseline
DK1303258T3 (da) Hidtil ukendte aerosolformuleringer, der indeholder et polært, floureret molekyle
BR0212857A (pt) Formulações e uso destas
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
HUP0002533A2 (hu) Asztmaellenes gyógyszerhatóanyagok új kombinációja
IT1260155B (it) Uso terapeutico della fosforil-l-serina-n-acil-sfingosina

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]